SMARTube™ as a Test for Recent Infection

Reshma Kassanjee^{1,2}, Alex Welte^{1,2}, Tamar Jehuda-Cohen³

¹ University of the Witwatersrand, South Africa
² South African DST/ NRF Centre for Epidemiological Modelling and Analysis, South Africa
³ Smart Biotech Ltd, Israel





Tests for Recent Infection (TRI's)

• What?

Classify infections as recently or non-recently acquired


• Why?


Incidence estimation Using cross-sectional surveys rather than prospective follow-up


• Challenges?


Achieve certain performance characteristics (**not** specificity / sensitivity) **Surveillance,** not **diagnostics**












Power in tests of incidence:

http://www0.sun.ac.za/sacema/collaboration/abie/

SMARTube[™] Technology


- Stimulating Maximal Antibody Response Tube
 - In-vitro stimulation of antibody producing B cells
 - Allows for earlier detection of HIV infection



Time after Infection

SMARTube™ Technology

- Stimulating Maximal Antibody Response Tube
 - In-vitro stimulation of antibody producing B cells
 - Allows for earlier detection of HIV infection





Time after Infection


- → Novel biomarker for a test for recent infection
 - Stimulation Index: SI =

Stimulated Antibody Level Unstimulated Antibody Level

Recent infection ↔ SI > SI Threshold







Conclusion

- Preliminary analysis provides promising results
- Test for recent infection using SMARTube™
 - Low false recent rate AND
 - High mean recency duration
- Recommend a larger dataset of better characterised specimens is analysed
- There is scope for non-traditional approaches for constructing tests for recent infection

To find out more ...

() SACEMA

Poster,

SMARTube™ Technology: Inspiration for Innovatively New Tests for Recent Infection

Reshma Kassanjee^{1,2}, Alex Welte^{1,2} and Tamar Jehuda-Cohen³



r.kassanjee@gmail.com, alex.welte@wits.ac.za and tamar@smartube-bio.com

¹University of the Witwatersrand, South Africa; ²South African DST/ NRF Centre for Epidemiological Modelling and Analysis, South Africa; ³Smart Biotech Ltd, Israel

Background and Significance	False Recent Rate of a Test for Recent Infection Using SMARTube™
Incidence (the rate at which new infections occur in a population) provides a more direct and current indication of the state of the HIV epidemic than does prevalence (the fraction of a population in an infected state at a point in time). Incidence measures provide invaluable information for assessing outbreaks, planning studies and targeting and assessing interventions.	Method of Estimation: The False Recent Rate (ϵ) is estimated by applying the TRI to a sample of seropositive individuals known to be non-recently infected. The proportion of these individuals indicated as being recently-infected by the TRI provides a maximum-likelihood estimate of the proportion of false-recent results, ϵ .
In the past, the measurement of incidence through the direct observation of new infections during the prospective follow-up of a cohort of initially seronegative individuals has been considered the 'gold standard' for incidence estimation. However, cohort studies are costly, logistically difficult to set-up and maintain, and results are prone to bias from unrepresentative recruitment and attrition of subjects.	Data: Data describing a sample of non-recently infected individuals attending CDC clinics are used. The data provides the SI value resulting when applying both the Abbott (n=59) and Wantai (n=73) diagnostic kits to unstimulated and stimulated plasma.
Tests for Recent Infection (TRI's) therefore provide an attractive means of estimating incidence without the need for prospective follow-up [1]. In recent years, there has been much interest and development in relating incidence to the prevalence of TRI-defined 'recent infections' [for example: 2, 3, 4, 5]. The Centers for Disease Control and Prevention (CDC) uses the term 'Serological Testing Algorithm for Recent HIV Seroconversion' (STARHS) to refer to a TRI in use.	Results: The decreasing estimates of ϵ , with increasing SI Thresholds, are illustrated in Figure 2 below. Two-sided 95% confidence intervals are also provided (Clopper-Pearson confidence intervals based on the binomial distribution of the number of TRI-recent results). The rapid decrease of the estimated ϵ as a function of SI Threshold suggests that a suitably low False Recent Rate may be achievable by the choice of an SI Threshold of 1.2 or larger.
TRI's classify infections as recently or non-recently acquired, based on the results of laboratory tests that quantify biomarkers which evolve with time after infection [6,7], sometimes supplemented by clinical information. The prevalence of the TRI-defined 'recent infections' is estimated by applying the TRI in a cross-sectional survey of the population of interest.	Testing for inferiority of a TRI based on SMARTube TM to existing tests, the data are used to assess H_0 : $\epsilon = 5\%$ vs H_1 : $\epsilon > 5\%$. Rejecting the null hypothesis, H_0 , would suggest that further investigation of such a TRI is not warranted. Even at a relatively low SI Threshol of 1.1, we fail to reject H_0 , with p-values of 0.80 and 0.71 for the Abbott and Wantai kits respectively. Figure 2: Estimated False Recent Rate as a Function of SI Threshold
Performance Characteristics of Tests for Recent Infection	
The classification of infections by a TRI is based on measured biomarkers [6,7]. The evolution of these biomarkers within infected individuals exhibit inter-subject variability.	Abbott Wantal

http://www0.sun.ac.za/sacema/collaboration/abie/, and Questions

Surveillance NOT Diagnostics

Why Specificity and Sensitivity are not of concern...

Example: Estimating the incidence of Flu



- Individuals remain infected for 3-7 days, average of 5 days
- Incidence \approx 'Prevalence' \div (5/365)
- Whether a particular person is still infected 4 days after infections is not of concern for incidence estimation